Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research focused on Radiation therapy and Propensity score matching, with related work in Oncology, Chemoradiotherapy, Lung cancer. Notable publications include 'Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy', 'Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized...', and 'Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey'.
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
Epidemiology, Prevention, and Treatment of Chemotherapy-Induced Myelosuppression in China: A National Cross-Sectional Study
Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma
98P Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy
Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey
Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis
Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
Correction to: A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
A Chinese Multi-Institutional Analysis of Three Dimensional Conformal Radiation or Intensity-Modulated Radiation Therapy for Non-Operated Localized Esophageal Squamous Cell Carcinoma in Definitive (Chemo)Radiation
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel
Definitive Intensity-Modulated Radiation Therapy With a Simultaneous Integrated Boost May Lead to Better Outcome for Non-operated Localized Esophageal Squamous Cell Carcinoma—Analysis from a Multicenter Study
Nomogram to Predict Prognosis in Thoracic Esophageal Squamous Cell Carcinoma After Neoadjuvant Radiation Therapy or Chemoradiation Therapy
Nimotuzumab combined with radiotherapy on esophageal cancer: Preliminary study of a phase II clinical trial.